<?xml version="1.0" encoding="UTF-8"?><xml><records><record><source-app name="Biblio" version="7.x">Drupal-Biblio</source-app><ref-type>17</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">Gajbhiye, J. M.</style></author><author><style face="normal" font="default" size="100%">More, Namita A.</style></author><author><style face="normal" font="default" size="100%">Patil, Manoj D.</style></author><author><style face="normal" font="default" size="100%">Ummanni, R.</style></author><author><style face="normal" font="default" size="100%">Kotapalli, S. S.</style></author><author><style face="normal" font="default" size="100%">Yogeeswari, P.</style></author><author><style face="normal" font="default" size="100%">Sriram, D.</style></author><author><style face="normal" font="default" size="100%">Masand, Vijay H.</style></author></authors></contributors><titles><title><style face="normal" font="default" size="100%">Discovery of rimonabant and its potential analogues as anti-TB drug candidates</style></title><secondary-title><style face="normal" font="default" size="100%">Medicinal Chemistry Research</style></secondary-title></titles><keywords><keyword><style  face="normal" font="default" size="100%">Diaryl pyrazoles</style></keyword><keyword><style  face="normal" font="default" size="100%">H37Rv</style></keyword><keyword><style  face="normal" font="default" size="100%">MTCYP-121</style></keyword><keyword><style  face="normal" font="default" size="100%">Mycobacterium tuberculosis</style></keyword><keyword><style  face="normal" font="default" size="100%">Rimonabant</style></keyword><keyword><style  face="normal" font="default" size="100%">tuberculosis</style></keyword></keywords><dates><year><style  face="normal" font="default" size="100%">2015</style></year><pub-dates><date><style  face="normal" font="default" size="100%">JUL</style></date></pub-dates></dates><number><style face="normal" font="default" size="100%">7</style></number><publisher><style face="normal" font="default" size="100%">SPRINGER BIRKHAUSER</style></publisher><pub-location><style face="normal" font="default" size="100%">233 SPRING STREET, 6TH FLOOR, NEW YORK, NY 10013 USA</style></pub-location><volume><style face="normal" font="default" size="100%">24</style></volume><pages><style face="normal" font="default" size="100%">2960-2971</style></pages><language><style face="normal" font="default" size="100%">eng</style></language><abstract><style face="normal" font="default" size="100%">&lt;p&gt;Rimonabant and its analogues have been synthesized in moderate to good yields using a simple synthetic route. All the newly synthesized compounds were subjected to in vitro screening against M. tuberculosis and M. smegmatis. The most potent analogue JMG-14 exhibits MIC value of 3.13 compared to 3.25 and 50 A mu g/ml for ethambutol and pyrazinamide, respectively. The molecular docking reveals that pyrazole ring, number and position of halogen atoms play a crucial role in deciding interactions with MTCYP-121. These findings open up a new avenue in the search of potent anti-TB drugs with rimonabant and its novel analogue JMG-14 as lead molecules.&lt;/p&gt;</style></abstract><issue><style face="normal" font="default" size="100%">7</style></issue><custom3><style face="normal" font="default" size="100%">&lt;p&gt;Foreign&lt;/p&gt;</style></custom3><custom4><style face="normal" font="default" size="100%">1.436</style></custom4></record></records></xml>